Corporate concessions

Corporates have argued initiatives to introduce over-the-counter derivatives regulation in the US and Europe will severely hamper their ability to hedge. After an intensive lobbying effort, the politicians appear to be listening. Matt Cameron reports

Pauline Wallace, PricewaterhouseCoopers

Since Lehman Brothers collapsed last year, the regulatory reform agenda has progressed with a sense of inevitability. Various bankers, hedge fund managers and industry representatives have stood in front of congressional hearings to give testimony on what they perceive to be the advantages of over-the-counter derivatives. For the most part, it has been to little avail - the push for regulatory reform has continued regardless. The past couple of months, however, have seen a shift. Following

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact or view our subscription options here:

You are currently unable to copy this content. Please contact to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to View our subscription options

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here